Search

Your search keyword '"Chiusolo, Patrizia"' showing total 1,292 results
Start Over Author "Chiusolo, Patrizia"
1,292 results on '"Chiusolo, Patrizia"'

151. Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML

Author

Metafuni, Elisabetta, primary, Amato, Viviana, additional, Giammarco, Sabrina, additional, Bellesi, Silvia, additional, Rossi, Monica, additional, Minnella, Gessica, additional, Frioni, Filippo, additional, Limongiello, Maria Assunta, additional, Pagano, Livio, additional, Bacigalupo, Andrea, additional, Sica, Simona, additional, and Chiusolo, Patrizia, additional

Published
2022
Full Text
View/download PDF

152. Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience

Author

Autore, Francesco, primary, Stirparo, Luca, additional, Innocenti, Idanna, additional, Papa, Elena, additional, Marchesi, Francesco, additional, Togni, Chiara, additional, Mariani, Sabrina, additional, Torrieri, Lorenzo, additional, Salvatori, Martina, additional, Fazio, Francesca, additional, Metafuni, Elisabetta, additional, Giammarco, Sabrina, additional, Sora, Federica, additional, Falcucci, Paolo, additional, Ferrari, Antonella, additional, Trisolini, Silvia Maria, additional, Capria, Saveria, additional, Tafuri, Agostino, additional, Chiusolo, Patrizia, additional, Sica, Simona, additional, and Laurenti, Luca, additional

Published
2022
Full Text
View/download PDF

153. 1464. Real-World (RW) Utilization Pattern of Letermovir in Adult Cytomegalovirus Seropositive Allogeneic Hematopoietic Stem Cell Transplant (HCT) Recipients: A Multicenter Retrospective Cohort Study from the European Society for Blood and Marrow Transplantation (EBMT) Registry

Author

Styczynski, Jan, primary, Tridello, Gloria, additional, Knelange, Nina, additional, Wendel, Lotus, additional, Xhaard, Alienor, additional, Cutini, Ilaria, additional, Chiusolo, Patrizia, additional, Franke, Georg-Nikolaus, additional, Kraus, Sabina, additional, Raval, Amit D, additional, Merchant, Sanjay, additional, and de la Camara, Rafael, additional

Published
2022
Full Text
View/download PDF

154. Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Author

Sauta, Elisabetta, primary, Robin, Marie, additional, Bersanelli, Matteo, additional, Travaglino, Erica, additional, Meggendorfer, Manja, additional, Zhao, Lin-Pierre, additional, Caballero Berrocal, Juan Carlos, additional, Maggioni, Giulia, additional, Tentori, Cristina Astrid, additional, Bernardi, Massimo, additional, Di Grazia, Carmen, additional, Vago, Luca, additional, Rivoli, Giulia, additional, Borin, Lorenza, additional, D'Amico, Saverio, additional, Ubezio, Marta, additional, Campagna, Alessia, additional, Russo, Antonio, additional, Mannina, Daniele, additional, Lanino, Luca, additional, Chiusolo, Patrizia, additional, Giaccone, Luisa, additional, Voso, Maria Teresa, additional, Riva, Marta, additional, Oliva, Esther Natalie, additional, Zampini, Matteo, additional, Riva, Elena, additional, Nibourel, Olivier, additional, Sala, Claudia, additional, Bicchieri, Marilena, additional, Bolli, Niccolò, additional, Rambaldi, Alessandro, additional, Passamonti, Francesco, additional, Savevski, Victor, additional, Santoro, Armando, additional, Germing, Ulrich, additional, Kordasti, Shahram, additional, Santini, Valeria, additional, Diez-Campelo, Maria, additional, Sanz, Guillermo, additional, Solé, Francesc, additional, Kern, Wolfgang, additional, Platzbecker, Uwe, additional, Ades, Lionel, additional, Fenaux, Pierre, additional, Haferlach, Torsten, additional, Gastone, Castellani, additional, and Della Porta, Matteo G., additional

Published
2022
Full Text
View/download PDF

155. Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis

Author

Hernandez Boluda, Juan Carlos, primary, Eikema, Dirk-Jan, additional, Erazo, Nadia, additional, Kröger, Nicolaus, additional, Robin, Marie, additional, de Witte, Moniek, additional, Finke, Jürgen, additional, Rambaldi, Alessandro, additional, Broers, Annoek E.C., additional, Raida, Ludek, additional, Schaap, Nicolaas, additional, Chiusolo, Patrizia, additional, Verbeek, Mareike, additional, Choi, Goda, additional, Halaburda, Kazimierz, additional, Kulagin, Alexander D., additional, Labussiere-Wallet, Helene, additional, Gedde-Dahl, Tobias, additional, Rabitsch, Werner, additional, Raj, Kavita, additional, Drozd-Sokolowska, Joanna, additional, Polverelli, Nicola, additional, Czerw, Tomasz, additional, Yakoub-Agha, Ibrahim, additional, and McLornan, Donal P., additional

Published
2022
Full Text
View/download PDF

156. Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia

Author

Cavallaro, Gianluca, primary, Grassi, Anna, additional, Pavoni, Chiara, additional, Mico', Maria Caterina, additional, Busca, Alessandro, additional, Cavattoni, Irene Maria, additional, Santarone, Stella, additional, Borghero, Carlo, additional, Olivieri, Attilio, additional, Milone, Giuseppe, additional, Chiusolo, Patrizia, additional, Musto, Pellegrino, additional, Saccardi, Riccardo, additional, Patriarca, Francesca, additional, Pane, Fabrizio, additional, Saporiti, Giorgia, additional, Rivela, Paolo, additional, Terruzzi, Elisabetta, additional, Cerretti, Raffaella, additional, Marotta, Giuseppe, additional, Carella, Angelo Michele, additional, Nagler, Arnon, additional, Russo, Domenico, additional, Corradini, Paolo, additional, Bernasconi, Paolo, additional, Iori, Anna Paola, additional, Castagna, Luca, additional, Mordini, Nicola, additional, Oldani, Elena, additional, Di Grazia, Carmen, additional, Bacigalupo, Andrea, additional, and Rambaldi, Alessandro, additional

Published
2022
Full Text
View/download PDF

157. Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Author

Baron, Frederic, primary, Labopin, Myriam, additional, Tischer, Johanna, additional, Raiola, Anna Maria, additional, Vydra, Jan, additional, Blaise, Didier, additional, Chiusolo, Patrizia, additional, Stölzel, Friedrich, additional, Fanin, Renato, additional, Chevallier, Patrice, additional, Nagler, Arnon, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

159. Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Author

Girmenia, Corrado, Raiola, Anna Maria, Piciocchi, Alfonso, Algarotti, Alessandra, Stanzani, Marta, Cudillo, Laura, Pecoraro, Clara, Guidi, Stefano, Iori, Anna Paola, Montante, Barbara, Chiusolo, Patrizia, Lanino, Edoardo, Carella, Angelo Michele, Zucchetti, Elisa, Bruno, Benedetto, Irrera, Giuseppe, Patriarca, Francesca, Baronciani, Donatella, Musso, Maurizio, Prete, Arcangelo, Risitano, Antonio Maria, Russo, Domenico, Mordini, Nicola, Pastore, Domenico, Vacca, Adriana, Onida, Francesco, Falcioni, Sadia, Pisapia, Giovanni, Milone, Giuseppe, Vallisa, Daniele, Olivieri, Attilio, Bonini, Alessandro, Castagnola, Elio, Sica, Simona, Majolino, Ignazio, Bosi, Alberto, Busca, Alessandro, Arcese, William, Bandini, Giuseppe, Bacigalupo, Andrea, Rambaldi, Alessandro, and Locasciulli, Anna

Published
2014
Full Text
View/download PDF

160. Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021

Author

Bacigalupo, Andrea, Innocenti, Idanna, Rossi, Elena, Sora', Federica, Galli, Eugenio, Autore, Francesco, Metafuni, Elisabetta, Chiusolo, Patrizia, Giammarco, Sabrina, Laurenti, Luca, Benintende, Giulia, Sica, Simona, De Stefano, Valerio, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Rossi, Elena (ORCID:0000-0002-7572-9379), Sora, Federica (ORCID:0000-0002-9607-5298), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Laurenti, Luca (ORCID:0000-0002-8327-1396), Sica, Simona (ORCID:0000-0003-2426-3465), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Bacigalupo, Andrea, Innocenti, Idanna, Rossi, Elena, Sora', Federica, Galli, Eugenio, Autore, Francesco, Metafuni, Elisabetta, Chiusolo, Patrizia, Giammarco, Sabrina, Laurenti, Luca, Benintende, Giulia, Sica, Simona, De Stefano, Valerio, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Rossi, Elena (ORCID:0000-0002-7572-9379), Sora, Federica (ORCID:0000-0002-9607-5298), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Laurenti, Luca (ORCID:0000-0002-8327-1396), Sica, Simona (ORCID:0000-0003-2426-3465), and De Stefano, Valerio (ORCID:0000-0002-5178-5827)

Abstract

The aim of this review is to update the current status of allogeneic hemopoietic stem cell transplants (HSCT) for patients with myelofibrosis (MF). We have first summarized the issue of an indication for allogeneic HSCT, discussing several prognostic scoring systems, developed to predict the outcome of MF, and therefore to identify patients who will benefit of an allogeneic HSCT. Patients with low risk MF are usually not selected for a transplant, whereas patients with intermediate or high risk MF are eligible. A separate issue, is how to predict the outcome of HSCT: we will outline a clinical molecular myelofibrosis transplant scoring system (MTSS), which predicts overall survival, ranging from 90% for low risk patients, to 20% for very high risk patients. We will also discuss transfusion burden and spleen size, as predictors of transplant outcome. The choice of a transplant platform including the conditioning regimen, the stem cell source and GvHD prophylaxis, are crucial for a successful program in MF, and will be outlined. Complications such as poor graft function, graft failure, GvHD and relapse of the disease, will also be reviewed. Finally we discuss monitoring the disease after HSCT with donor chimerism, driver mutations and hematologic data. We have made an effort to make this review as comprehensive and up to date as possible, and we hope it will provide some useful data for the clinicians.

Published
2021

161. Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review

Author

Sora', Federica, Annunziata, Mario, Laurenti, Luca, Giammarco, Sabrina, Chiusolo, Patrizia, Innocenti, Idanna, Autore, Francesco, Metafuni, Elisabetta, Galli, Eugenio, Bacigalupo, Andrea, Ferrara, Felicetto, Sica, Simona, Sora, Federica (ORCID:0000-0002-9607-5298), Laurenti, Luca (ORCID:0000-0002-8327-1396), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Sora', Federica, Annunziata, Mario, Laurenti, Luca, Giammarco, Sabrina, Chiusolo, Patrizia, Innocenti, Idanna, Autore, Francesco, Metafuni, Elisabetta, Galli, Eugenio, Bacigalupo, Andrea, Ferrara, Felicetto, Sica, Simona, Sora, Federica (ORCID:0000-0002-9607-5298), Laurenti, Luca (ORCID:0000-0002-8327-1396), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), and Bacigalupo, Andrea (ORCID:0000-0002-9119-567X)

Abstract

NOT AVAILABLE

Published
2021

162. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen

Author

Chiusolo, Patrizia, Bregante, Stefania, Giammarco, Sabrina, Lamparelli, Teresa, Casarino, Lucia, Dominietto, Alida, Raiola Anna, Maria, Metafuni, Elisabetta, Di Grazia, Carmen, Gualandi, Francesca, Sora', Federica, Laurenti, Luca, Sica, Simona, Barosi, Gianni, Guolo, Fabio, Rossi, Monica, Rossi, Elena, Vannucchi, Alessandro, Signori, Alessio, De Stefano, Valerio, Bacigalupo, Andrea, Angelucci, Emanuele, Chiusolo Patrizia (ORCID:0000-0002-1355-1587), Metafuni Elisabetta, Sora Federica (ORCID:0000-0002-9607-5298), Laurenti Luca (ORCID:0000-0002-8327-1396), Sica Simona (ORCID:0000-0003-2426-3465), Rossi Monica, Rossi Elena (ORCID:0000-0002-7572-9379), De Stefano Valerio (ORCID:0000-0002-5178-5827), Bacigalupo Andrea (ORCID:0000-0002-9119-567X), Chiusolo, Patrizia, Bregante, Stefania, Giammarco, Sabrina, Lamparelli, Teresa, Casarino, Lucia, Dominietto, Alida, Raiola Anna, Maria, Metafuni, Elisabetta, Di Grazia, Carmen, Gualandi, Francesca, Sora', Federica, Laurenti, Luca, Sica, Simona, Barosi, Gianni, Guolo, Fabio, Rossi, Monica, Rossi, Elena, Vannucchi, Alessandro, Signori, Alessio, De Stefano, Valerio, Bacigalupo, Andrea, Angelucci, Emanuele, Chiusolo Patrizia (ORCID:0000-0002-1355-1587), Metafuni Elisabetta, Sora Federica (ORCID:0000-0002-9607-5298), Laurenti Luca (ORCID:0000-0002-8327-1396), Sica Simona (ORCID:0000-0003-2426-3465), Rossi Monica, Rossi Elena (ORCID:0000-0002-7572-9379), De Stefano Valerio (ORCID:0000-0002-5178-5827), and Bacigalupo Andrea (ORCID:0000-0002-9119-567X)

Abstract

The aim of this retrospective study was to assess the rate of full donor chimerism (F-DC) in patients with myelofibrosis, prepared for an allogeneic stem cell transplant, with one or two alkylating agents. We analyzed 120 patients with myelofibrosis, for whom chimerism data were available on day +30. There were two groups: 42 patients were conditioned with one alkylating agent (ONE-ALK), either thiotepa or busulfan or melphalan, in combination with fludarabine, whereas 78 patients were prepared with two alkylating agents, thiotepa busulfan and fludarabine (TBF). Patients receiving TBF were older (57 vs 52 years), were less frequently splenectomized pre-HSCT (31% vs 59%), had more frequently intermediate-2/high DIPSS scores (90% vs 74%), were grafted more frequently from alternative donors (83% vs 33%) and received more frequently ruxolitinib pre-HSCT (26% vs 7%). The proportion of patients with F-DC on day +30, in the TBF vs the ONE-ALK group, was respectively 87% vs 45% (P < .001). The 5-year cumulative incidence of relapse was 9% in the TBF group, vs 43% for the ONE-ALK group (P < .001). The 5-year actuarial disease-free survival was 63% for TBF and 38% for the ONE-ALK group (P = .004). In conclusion, early full donor chimerism is a prerequisite for long term control of disease in patients with myelofibrosis, undergoing an allogeneic HSCT. The combination of two alkylating agents in the conditioning regimen, provides a higher chance of achieving full donor chimerism on day+30, and thus a higher chance of long term disease free survival.

Published
2021

163. A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19

Author

Murri, Rita, Lenkowicz, Jacopo, Masciocchi, Carlotta, Iacomini, Chiara, Fantoni, Massimo, Damiani, Andrea, Marchetti, Antonio, Sergi, Paolo Domenico Angelo, Arcuri, Giovanni, Cesario, Alfredo, Patarnello, Stefano, Antonelli, Massimo, Bellantone, Rocco Domenico Alfonso, Bernabei, Roberto, Boccia, Stefania, Calabresi, Paolo, Cambieri, Andrea, Cauda, Roberto, Colosimo, Cesare, Crea, Filippo, De Maria Marchiano, Ruggero, De Stefano, Valerio, Franceschi, Francesco, Gasbarrini, Antonio, Parolini, Ornella, Richeldi, Luca, Sanguinetti, Maurizio, Urbani, Andrea, Zega, Maurizio, Scambia, Giovanni, Valentini, Vincenzo, Armuzzi, Alessandro, Barba, Marta, Baroni, Silvia, Bellesi, Silvia, Bentivoglio, Annarita, Biasucci, Luigi Marzio, Biscetti, Federico, Candelli, Marcello, Capalbo, Gennaro, Cattani Franchi, Paola, Chiusolo, Patrizia, Cingolani, Antonella, Corbo, Giuseppe Maria, Covino, Marcello, Cozzolino, Angela Maria, D’Alfonso, Marilena, De Angelis, Giulia, De Pascale, Gennaro, Frisullo, Giovanni, Gabrielli, Maurizio, Gambassi, Giovanni, Garcovich, Matteo, Gremese, Elisa, Grieco, Domenico Luca, Iaconelli, Amerigo, Iorio, Raffaele, Landi, Francesco, Larici, Annarita, Liuzzo, Giovanna, Maviglia, Riccardo, Miele, Luca, Montalto, Massimo, Natale, Luigi, Nicolotti, Nicola, Ojetti, Veronica, Pompili, Maurizio, Posteraro, Brunella, Rapaccini, Gianni, Rinaldi, Riccardo, Rossi, Elena, Santoliquido, Angelo, Sica, Simona, Tamburrini, Enrica, Teofili, Luciana, Testa, Antonia Carla, Tosoni, Alberto, Trani, Carlo, Varone, Francesco, Zileri Dal Verme, Lorenzo, Null, Null, Murri, Rita (ORCID:0000-0003-4263-7854), Fantoni, Massimo (ORCID:0000-0001-6913-8460), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Antonelli, Massimo (ORCID:0000-0003-3007-1670), Bellantone, Rocco (ORCID:0000-0002-0844-3469), Bernabei, Roberto (ORCID:0000-0002-9197-004X), Boccia, Stefania (ORCID:0000-0002-1864-749X), Calabresi, Paolo (ORCID:0000-0003-0326-5509), Cauda, Roberto (ORCID:0000-0002-1498-4229), Colosimo, Cesare (ORCID:0000-0003-3800-3648), Crea, Filippo (ORCID:0000-0001-9404-8846), De Maria, Ruggero (ORCID:0000-0003-2255-0583), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Parolini, Ornella (ORCID:0000-0002-5211-6430), Richeldi, Luca (ORCID:0000-0001-8594-1448), Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Zega, Maurizio (ORCID:0000-0002-7821-2615), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Barba, Marta (ORCID:0000-0001-6084-7666), Baroni, Silvia (ORCID:0000-0002-3410-2617), Biasucci, Luigi Marzio (ORCID:0000-0002-6921-6497), Biscetti, Federico (ORCID:0000-0001-7449-657X), Candelli, Marcello (ORCID:0000-0001-8443-7880), Cattani, Paola (ORCID:0000-0003-4678-4763), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Cingolani, Antonella (ORCID:0000-0002-3793-2755), Corbo, Giuseppe (ORCID:0000-0002-8104-4659), Covino, Marcello (ORCID:0000-0002-6709-2531), De Angelis, Giulia (ORCID:0000-0002-7087-7399), De Pascale, Gennaro (ORCID:0000-0002-8255-0676), Gambassi, Giovanni (ORCID:0000-0002-7030-9359), Gremese, Elisa (ORCID:0000-0002-2248-1058), Grieco, Domenico Luca (ORCID:0000-0002-4557-6308), Iorio, Raffaele (ORCID:0000-0002-6270-0956), Landi, Francesco (ORCID:0000-0002-3472-1389), Liuzzo, Giovanna (ORCID:0000-0002-5714-0907), Miele, Luca (ORCID:0000-0003-3464-0068), Montalto, Massimo (ORCID:0000-0001-8819-3684), Natale, Luigi (ORCID:0000-0002-7949-5119), Ojetti, Veronica (ORCID:0000-0002-8953-0707), Pompili, Maurizio (ORCID:0000-0001-6699-7980), Posteraro, Brunella (ORCID:0000-0002-1663-7546), Rossi, Elena (ORCID:0000-0002-7572-9379), Santoliquido, Angelo (ORCID:0000-0003-1539-4017), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), Teofili, Luciana (ORCID:0000-0002-7214-1561), Testa, Antonia (ORCID:0000-0003-2217-8726), Trani, Carlo (ORCID:0000-0001-9777-013X), Verme, Lorenzo Zileri Dal, Murri, Rita, Lenkowicz, Jacopo, Masciocchi, Carlotta, Iacomini, Chiara, Fantoni, Massimo, Damiani, Andrea, Marchetti, Antonio, Sergi, Paolo Domenico Angelo, Arcuri, Giovanni, Cesario, Alfredo, Patarnello, Stefano, Antonelli, Massimo, Bellantone, Rocco Domenico Alfonso, Bernabei, Roberto, Boccia, Stefania, Calabresi, Paolo, Cambieri, Andrea, Cauda, Roberto, Colosimo, Cesare, Crea, Filippo, De Maria Marchiano, Ruggero, De Stefano, Valerio, Franceschi, Francesco, Gasbarrini, Antonio, Parolini, Ornella, Richeldi, Luca, Sanguinetti, Maurizio, Urbani, Andrea, Zega, Maurizio, Scambia, Giovanni, Valentini, Vincenzo, Armuzzi, Alessandro, Barba, Marta, Baroni, Silvia, Bellesi, Silvia, Bentivoglio, Annarita, Biasucci, Luigi Marzio, Biscetti, Federico, Candelli, Marcello, Capalbo, Gennaro, Cattani Franchi, Paola, Chiusolo, Patrizia, Cingolani, Antonella, Corbo, Giuseppe Maria, Covino, Marcello, Cozzolino, Angela Maria, D’Alfonso, Marilena, De Angelis, Giulia, De Pascale, Gennaro, Frisullo, Giovanni, Gabrielli, Maurizio, Gambassi, Giovanni, Garcovich, Matteo, Gremese, Elisa, Grieco, Domenico Luca, Iaconelli, Amerigo, Iorio, Raffaele, Landi, Francesco, Larici, Annarita, Liuzzo, Giovanna, Maviglia, Riccardo, Miele, Luca, Montalto, Massimo, Natale, Luigi, Nicolotti, Nicola, Ojetti, Veronica, Pompili, Maurizio, Posteraro, Brunella, Rapaccini, Gianni, Rinaldi, Riccardo, Rossi, Elena, Santoliquido, Angelo, Sica, Simona, Tamburrini, Enrica, Teofili, Luciana, Testa, Antonia Carla, Tosoni, Alberto, Trani, Carlo, Varone, Francesco, Zileri Dal Verme, Lorenzo, Null, Null, Murri, Rita (ORCID:0000-0003-4263-7854), Fantoni, Massimo (ORCID:0000-0001-6913-8460), Cesario, Alfredo (ORCID:0000-0003-4687-0709), Antonelli, Massimo (ORCID:0000-0003-3007-1670), Bellantone, Rocco (ORCID:0000-0002-0844-3469), Bernabei, Roberto (ORCID:0000-0002-9197-004X), Boccia, Stefania (ORCID:0000-0002-1864-749X), Calabresi, Paolo (ORCID:0000-0003-0326-5509), Cauda, Roberto (ORCID:0000-0002-1498-4229), Colosimo, Cesare (ORCID:0000-0003-3800-3648), Crea, Filippo (ORCID:0000-0001-9404-8846), De Maria, Ruggero (ORCID:0000-0003-2255-0583), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Parolini, Ornella (ORCID:0000-0002-5211-6430), Richeldi, Luca (ORCID:0000-0001-8594-1448), Sanguinetti, Maurizio (ORCID:0000-0002-9780-7059), Zega, Maurizio (ORCID:0000-0002-7821-2615), Scambia, Giovanni (ORCID:0000-0003-2758-1063), Valentini, Vincenzo (ORCID:0000-0003-4637-6487), Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Barba, Marta (ORCID:0000-0001-6084-7666), Baroni, Silvia (ORCID:0000-0002-3410-2617), Biasucci, Luigi Marzio (ORCID:0000-0002-6921-6497), Biscetti, Federico (ORCID:0000-0001-7449-657X), Candelli, Marcello (ORCID:0000-0001-8443-7880), Cattani, Paola (ORCID:0000-0003-4678-4763), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Cingolani, Antonella (ORCID:0000-0002-3793-2755), Corbo, Giuseppe (ORCID:0000-0002-8104-4659), Covino, Marcello (ORCID:0000-0002-6709-2531), De Angelis, Giulia (ORCID:0000-0002-7087-7399), De Pascale, Gennaro (ORCID:0000-0002-8255-0676), Gambassi, Giovanni (ORCID:0000-0002-7030-9359), Gremese, Elisa (ORCID:0000-0002-2248-1058), Grieco, Domenico Luca (ORCID:0000-0002-4557-6308), Iorio, Raffaele (ORCID:0000-0002-6270-0956), Landi, Francesco (ORCID:0000-0002-3472-1389), Liuzzo, Giovanna (ORCID:0000-0002-5714-0907), Miele, Luca (ORCID:0000-0003-3464-0068), Montalto, Massimo (ORCID:0000-0001-8819-3684), Natale, Luigi (ORCID:0000-0002-7949-5119), Ojetti, Veronica (ORCID:0000-0002-8953-0707), Pompili, Maurizio (ORCID:0000-0001-6699-7980), Posteraro, Brunella (ORCID:0000-0002-1663-7546), Rossi, Elena (ORCID:0000-0002-7572-9379), Santoliquido, Angelo (ORCID:0000-0003-1539-4017), Tamburrini, Enrica (ORCID:0000-0003-4930-426X), Teofili, Luciana (ORCID:0000-0002-7214-1561), Testa, Antonia (ORCID:0000-0003-2217-8726), Trani, Carlo (ORCID:0000-0001-9777-013X), and Verme, Lorenzo Zileri Dal

Abstract

The COVID-19 pandemic is impressively challenging the healthcare system. Several prognostic models have been validated but few of them are implemented in daily practice. The objective of the study was to validate a machine-learning risk prediction model using easy-to-obtain parameters to help to identify patients with COVID-19 who are at higher risk of death. The training cohort included all patients admitted to Fondazione Policlinico Gemelli with COVID-19 from March 5, 2020, to November 5, 2020. Afterward, the model was tested on all patients admitted to the same hospital with COVID-19 from November 6, 2020, to February 5, 2021. The primary outcome was in-hospital case-fatality risk. The out-of-sample performance of the model was estimated from the training set in terms of Area under the Receiving Operator Curve (AUROC) and classification matrix statistics by averaging the results of fivefold cross validation repeated 3-times and comparing the results with those obtained on the test set. An explanation analysis of the model, based on the SHapley Additive exPlanations (SHAP), is also presented. To assess the subsequent time evolution, the change in paO2/FiO2 (P/F) at 48 h after the baseline measurement was plotted against its baseline value. Among the 921 patients included in the training cohort, 120 died (13%). Variables selected for the model were age, platelet count, SpO2, blood urea nitrogen (BUN), hemoglobin, C-reactive protein, neutrophil count, and sodium. The results of the fivefold cross-validation repeated 3-times gave AUROC of 0.87, and statistics of the classification matrix to the Youden index as follows: sensitivity 0.840, specificity 0.774, negative predictive value 0.971. Then, the model was tested on a new population (n=1463) in which the case-fatality rate was 22.6%. The test model showed AUROC 0.818, sensitivity 0.813, specificity 0.650, negative predictive value 0.922. Considering the first quartile of the predicted risk score (low-risk score gro

Published
2021

166. Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation

Author

Chiusolo, Patrizia, primary, Orlando, Nicoletta, additional, Giammarco, Sabrina, additional, Rossi, Monica, additional, Metafuni, Elisabetta, additional, Leotta, Salvatore, additional, Milone, Giuseppe, additional, Valentini, Caterina Giovanna, additional, Bianchi, Maria, additional, Frioni, Filippo, additional, Pellegrino, Claudio, additional, Sorà, Federica, additional, Larocca, Luigi Maria, additional, Sica, Simona, additional, Bacigalupo, Andrea, additional, and Teofili, Luciana, additional

Published
2022
Full Text
View/download PDF

167. A common pattern of somatic mutations in t‐MDS / AML of patients treated with PARP inhibitors for metastatic ovarian cancer

Author

Chiusolo, Patrizia, primary, Marchetti, Claudia, additional, Rossi, Monica, additional, Minnella, Gessica, additional, Salutari, Vanda, additional, Distefano, Mariagrazia, additional, Giammarco, Sabrina, additional, Metafuni, Elisabetta, additional, Minucci, Angelo, additional, Frioni, Filippo, additional, Gasbarrino, Cristiana, additional, Colangelo, Maria, additional, Orteschi, Daniela, additional, Fagotti, Anna, additional, Lorusso, Domenica, additional, Pagano, Livio, additional, De Stefano, Valerio, additional, Scambia, Giovanni, additional, and Sica, Simona, additional

Published
2022
Full Text
View/download PDF

168. Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients

Author

Chiusolo, Patrizia, primary, Metafuni, Elisabetta, additional, Minnella, Gessica, additional, Giammarco, Sabrina, additional, Bellesi, Silvia, additional, Rossi, Monica, additional, Sorà, Federica, additional, Limongiello, Maria Assunta, additional, Frioni, Filippo, additional, Piccirillo, Nicola, additional, Bianchi, Maria, additional, Valentini, Caterina Giovanna, additional, Teofili, Luciana, additional, Sica, Simona, additional, and Bacigalupo, Andrea, additional

Published
2022
Full Text
View/download PDF

169. SARS CoV 2 infection in chronic myelogenous leukemia: Severe hematological presentation

Author

Sora', Federica, Chiusolo, Patrizia, Laurenti, Luca, Innocenti, Idanna, Autore, Francesco, Alma, Eleonora, Viscovo, Marcello, Fusco, Domernico, Maresca, Maddalena, Tumbarello, Mario, Sica, Simona, Sorà, Federica (ORCID:0000-0002-9607-5298), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Laurenti, Luca (ORCID:0000-0002-8327-1396), Tumbarello, Mario (ORCID:0000-0002-9519-8552), Sica, Simona (ORCID:0000-0003-2426-3465), Sora', Federica, Chiusolo, Patrizia, Laurenti, Luca, Innocenti, Idanna, Autore, Francesco, Alma, Eleonora, Viscovo, Marcello, Fusco, Domernico, Maresca, Maddalena, Tumbarello, Mario, Sica, Simona, Sorà, Federica (ORCID:0000-0002-9607-5298), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Laurenti, Luca (ORCID:0000-0002-8327-1396), Tumbarello, Mario (ORCID:0000-0002-9519-8552), and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

N/A

Published
2020

170. Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms

Author

Schino, Mattia, Fiorentino, Vincenzo, Rossi, Elena, Betti, Silvia, Di Cecca, Monica, Ranucci, Valentina, Chiusolo, Patrizia, Martini, Maurizio, De Stefano, Valerio, Larocca, Luigi Maria, Rossi, Elena (ORCID:0000-0002-7572-9379), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Martini, Maurizio (ORCID:0000-0002-6260-6310), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Larocca, Luigi Maria (ORCID:0000-0003-1739-4758), Schino, Mattia, Fiorentino, Vincenzo, Rossi, Elena, Betti, Silvia, Di Cecca, Monica, Ranucci, Valentina, Chiusolo, Patrizia, Martini, Maurizio, De Stefano, Valerio, Larocca, Luigi Maria, Rossi, Elena (ORCID:0000-0002-7572-9379), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Martini, Maurizio (ORCID:0000-0002-6260-6310), De Stefano, Valerio (ORCID:0000-0002-5178-5827), and Larocca, Luigi Maria (ORCID:0000-0003-1739-4758)

Abstract

Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) have been traditionally considered as indistinctly slowly progressing conditions; recent evidence proves that a subset of cases have a rapid evolution, so that MPNs' prognosis needs to be personalized. We identified a new morphological parameter, defined as Megakaryocytic Activation (M-ACT) based on the coexistence of megakaryocytic emperipolesis, megakaryocytes (MK) clusters formation and evidence of arrangement of collagen fibers around the perimeter of MK. We retrospectively analyzed the bone marrow biopsy of two MPNs cohorts of patients with polycythemia (PV) (n=64) and non-PV patients [including essential thrombocythemia (ET), and early/prefibrotic primary myelofibrosis (PMF)] (n=222). M-ACT showed a significant correlation with splenomegaly, white blood cell (WBC) count, and LDH serum levels in both groups, with JAK2 V617F allele burden in PV patients, and with CALR mutations, and platelet count in non-PV patients. Progression-free survival, defined as PV-to-secondary MF progression and non-PV-to-overt PMF, was worse in both PV and early/prefibrotic PMF patients with M-ACT in comparison to those without M-ACT (P<.0001). Interestingly, M-ACT was not found in the subgroup of ET patients. In conclusion, M-ACT can be helpful in the differential diagnosis of MPNs and can represent a new morphologic parameter with a predictive value for progression of MPNs.

Published
2020

171. Bone marrow haploidentical transplant with post-transplantation cyclophosphamide :does graft cell content have an impact on main clinical outcomes?

Author

Bacigalupo, Andrea, Teofili, Luciana, Chiusolo, Patrizia, Valentini, Giovanna, Metafuni, Elisabetta, Bellesi, Silvia, Orlando, Nicoletta, Bianchi, Maria, Sica, Simona, Bacigalupo andrea (ORCID:0000-0002-9119-567X), Teofili Lucian (ORCID:0000-0002-7214-1561), Chiusolo Patrizia (ORCID:0000-0002-1355-1587), Metafuni Elisabetta, Bellesi Silvia, Orlando Nicoletta, Bianchi Maria, Sica Simona (ORCID:0000-0003-2426-3465), Bacigalupo, Andrea, Teofili, Luciana, Chiusolo, Patrizia, Valentini, Giovanna, Metafuni, Elisabetta, Bellesi, Silvia, Orlando, Nicoletta, Bianchi, Maria, Sica, Simona, Bacigalupo andrea (ORCID:0000-0002-9119-567X), Teofili Lucian (ORCID:0000-0002-7214-1561), Chiusolo Patrizia (ORCID:0000-0002-1355-1587), Metafuni Elisabetta, Bellesi Silvia, Orlando Nicoletta, Bianchi Maria, and Sica Simona (ORCID:0000-0003-2426-3465)

Abstract

We analyzed data relative to cell content in 88 consecutive patients receiving HLA haploidentical bone marrow (BM) transplants with post-transplantation cyclophosphamide (PT-CY). Median age was 54.5 (range, 17-72); diagnoses were acute leukemia (n = 46), lymphoproliferative disorders (n = 24), myelofibrosis (n = 11) and myelodysplastic syndromes (n = 5). Total nucleated cell (TNC) and CD34+, CD3+, CD4+ and CD8+ cell doses were stratified as higher than first, second and third quartile and the dose effect on various clinical outcomes was assessed. Median time to engraftment was 17 days for neutrophils and 24 days for platelets. To receive a dose of TNC ≥3.2 x 106/kg or CD34+ cells ≥2.7 x 106/kg significantly shortened the time to neutrophil and platelet engraftment and reduced the blood product requirements in the 30-day period after transplantation. Overall, TNC and CD34+ cell doses had no effect on acute graft-versus-host disease (GVHD) incidence, whereas patients receiving higher CD3+ and CD8+ cell doses seemed to have less chronic GVHD. No effect on non-relapse mortality, progression-free survival and overall survival was observed at different cell dose thresholds. These data suggest that in HLA haploidentical BM transplant with PT-CY, appropriate cell doses are relevant to the engraftment. The association between low CD3+/CD8+ cells and chronic GVHD deserves further investigation.

Published
2020

173. Pre-transplant gene profiling characterization by next-generation DNA sequencing might predict relapse occurrence after hematopoietic stem cell transplantation in patients affected by AML

Author

Metafuni, Elisabetta, Amato, Viviana, Giammarco, Sabrina, Bellesi, Silvia, Rossi, Monica, Minnella, Gessica, Frioni, Filippo, Assunta Limongiello, Maria, Pagano, Livio, Bacigalupo, Andrea, Sica, Simona, Chiusolo, Patrizia, Elisabetta Metafuni, Silvia Bellesi, Monica Rossi, Gessica Minnella, Filippo Frioni, Livio Pagano (ORCID:0000-0001-8287-928X), Andrea Bacigalupo (ORCID:0000-0002-9119-567X), Simona Sica (ORCID:0000-0003-2426-3465), Patrizia Chiusolo (ORCID:0000-0002-1355-1587), Metafuni, Elisabetta, Amato, Viviana, Giammarco, Sabrina, Bellesi, Silvia, Rossi, Monica, Minnella, Gessica, Frioni, Filippo, Assunta Limongiello, Maria, Pagano, Livio, Bacigalupo, Andrea, Sica, Simona, Chiusolo, Patrizia, Elisabetta Metafuni, Silvia Bellesi, Monica Rossi, Gessica Minnella, Filippo Frioni, Livio Pagano (ORCID:0000-0001-8287-928X), Andrea Bacigalupo (ORCID:0000-0002-9119-567X), Simona Sica (ORCID:0000-0003-2426-3465), and Patrizia Chiusolo (ORCID:0000-0002-1355-1587)

Abstract

Background: In the last decade, many steps forward have been made in acute myeloid leukemia prognostic stratification, adding next-generation sequencing techniques to the conventional molecular assays. This resulted in the revision of the current risk classification and the introduction of new target therapies. Aims and methods: We wanted to evaluate the prognostic impact of acute myeloid leukemia (AML) mutational pattern on relapse occurrence and survival after allogeneic stem cell transplantation. A specific next-generation sequencing (NGS) panel containing 26 genes was designed for the study. Ninety-six patients studied with NGS at diagnosis were included and retrospectively studied for post-transplant outcomes. Results: Only eight patients did not show any mutations. Multivariate Cox regression revealed FLT3 (HR, 3.36; p=0.02), NRAS (HR, 4.78; p=0.01), TP53 (HR, 4.34; p=0.03), and WT1 (HR 5.97; p=0.005) mutations as predictive variables for relapse occurrence after transplantation. Other independent variables for relapse recurrence were donor age (HR, 0.97; p=0.04), the presence of an adverse cytogenetic risk at diagnosis (HR, 3.03; p=0.04), and the obtainment of complete remission of the disease before transplantation (HR, 0.23; p=0.001). Overall survival appeared to be affected only by grade 2-4 acute GvHD occurrence (HR, 2.29; p=0.05) and relapse occurrence (HR, 4.33; p=0.0001) in multivariate analysis. Conclusions: The small number of patients and the retrospective design of the study might affect the resonance of our data. Although results on TP53, FLT3, and WT1 were comparable to previous reports, the interesting data on NRAS deserve attention.

Published
2022

174. Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T

Author

Galli, Eugenio, Sorà, F, Hohaus, Stefan, Fresa, Alberto, Pansini, Ilaria, Autore, Francesco, Metafuni, Elisabetta, Innocenti, Idanna, Limongiello, Ma, Giammarco, S, Laurenti, Luca, Bacigalupo, Andrea, Chiusolo, Patrizia, De Stefano, Valerio, Sica, Simona, Galli E, Hohaus S (ORCID:0000-0002-5534-7197), Fresa A, Pansini I, Autore F, Metafuni E, Innocenti I, Laurenti L (ORCID:0000-0002-8327-1396), Bacigalupo A (ORCID:0000-0002-9119-567X), Chiusolo P (ORCID:0000-0002-1355-1587), De Stefano V (ORCID:0000-0002-5178-5827), Sica S. (ORCID:0000-0003-2426-3465), Galli, Eugenio, Sorà, F, Hohaus, Stefan, Fresa, Alberto, Pansini, Ilaria, Autore, Francesco, Metafuni, Elisabetta, Innocenti, Idanna, Limongiello, Ma, Giammarco, S, Laurenti, Luca, Bacigalupo, Andrea, Chiusolo, Patrizia, De Stefano, Valerio, Sica, Simona, Galli E, Hohaus S (ORCID:0000-0002-5534-7197), Fresa A, Pansini I, Autore F, Metafuni E, Innocenti I, Laurenti L (ORCID:0000-0002-8327-1396), Bacigalupo A (ORCID:0000-0002-9119-567X), Chiusolo P (ORCID:0000-0002-1355-1587), De Stefano V (ORCID:0000-0002-5178-5827), and Sica S. (ORCID:0000-0003-2426-3465)

Abstract

Cytokine release syndrome (CRS) and consumptive coagulopathy can complicate the treatment with chimeric antigen receptor T (CAR-T) cells. The modified version of the Endothelial Activation and Stress Index (mEASIX), a score derived from haematopoietic stem cell transplantation, combines platelets, C-reactive protein (CRP), and lactate dehydrogenase (LDH) and has been correlated with CRS and endothelial biomarkers. In 38 consecutive patients with aggressive lymphoproliferative disease we measured a coagulative laboratory panel at baseline and early after infusion of anti-CD19 CAR-T. The panel was investigated also in the presence of CRS graded 2 or higher, or immune effector cell-associated neurotoxicity syndrome (ICANS). Moreover, we examined the relationship between mEASIX, coagulation biomarkers, and toxicities of CAR-T cells. During CRS grade 2 or higher, we found increased prothrombin time (PT) and activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, factor VIII (FVIII), and von Willebrand factor (vWF) antigen levels, and decreased platelet count and antithrombin levels. The occurrence of immune effector cell-associated neurotoxicity syndrome was associated with higher PT values, D-dimer, FVIII, and vWF levels, and decreased fibrinogen levels and platelet count. A higher mEASIX score correlated with increased aPTT values, fibrinogen, D-dimer, FVIII and vWF levels, and decreased antithrombin levels. Baseline mEASIX was predictive for consumptive coagulopathy and CRS graded 2 or higher, and for progression-free survival and overall survival.

Published
2022

175. VEGF and IL-6 Correlation in POEMS: A Potential Upcoming Marker of Active Disease and Early Autologous BMT Response

Author

Tomasso, Annamaria, Innocenti, Idanna, Autore, Francesco, Fresa, Alberto, Benintende, G., Vuono, Florenzia, Baroni, Silvia, Giannotta, C., Chiusolo, Patrizia, Sora', Federica, Sica, Simona, Laurenti, Luca, Tomasso A., Innocenti I., Autore F., Fresa A., Vuono F., Baroni S. (ORCID:0000-0002-3410-2617), Chiusolo P. (ORCID:0000-0002-1355-1587), Sora F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), Laurenti L. (ORCID:0000-0002-8327-1396), Tomasso, Annamaria, Innocenti, Idanna, Autore, Francesco, Fresa, Alberto, Benintende, G., Vuono, Florenzia, Baroni, Silvia, Giannotta, C., Chiusolo, Patrizia, Sora', Federica, Sica, Simona, Laurenti, Luca, Tomasso A., Innocenti I., Autore F., Fresa A., Vuono F., Baroni S. (ORCID:0000-0002-3410-2617), Chiusolo P. (ORCID:0000-0002-1355-1587), Sora F. (ORCID:0000-0002-9607-5298), Sica S. (ORCID:0000-0003-2426-3465), and Laurenti L. (ORCID:0000-0002-8327-1396)

Abstract

N/A

Published
2022

176. Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021

Author

Bacigalupo, Andrea, Innocenti, Idanna, Rossi, Elena, Sora', Federica, Galli, Eugenio, Autore, Francesco, Metafuni, Elisabetta, Chiusolo, Patrizia, Giammarco, S., Laurenti, Luca, Benintende, G., Sica, Simona, De Stefano, Valerio, Bacigalupo A. (ORCID:0000-0002-9119-567X), Innocenti I., Rossi E. (ORCID:0000-0002-7572-9379), Sora F. (ORCID:0000-0002-9607-5298), Galli E., Autore F., Metafuni E., Chiusolo P. (ORCID:0000-0002-1355-1587), Laurenti L. (ORCID:0000-0002-8327-1396), Sica S. (ORCID:0000-0003-2426-3465), De Stefano V. (ORCID:0000-0002-5178-5827), Bacigalupo, Andrea, Innocenti, Idanna, Rossi, Elena, Sora', Federica, Galli, Eugenio, Autore, Francesco, Metafuni, Elisabetta, Chiusolo, Patrizia, Giammarco, S., Laurenti, Luca, Benintende, G., Sica, Simona, De Stefano, Valerio, Bacigalupo A. (ORCID:0000-0002-9119-567X), Innocenti I., Rossi E. (ORCID:0000-0002-7572-9379), Sora F. (ORCID:0000-0002-9607-5298), Galli E., Autore F., Metafuni E., Chiusolo P. (ORCID:0000-0002-1355-1587), Laurenti L. (ORCID:0000-0002-8327-1396), Sica S. (ORCID:0000-0003-2426-3465), and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

The aim of this review is to update the current status of allogeneic hemopoietic stem cell transplants (HSCT) for patients with myelofibrosis (MF). We have first summarized the issue of an indication for allogeneic HSCT, discussing several prognostic scoring systems, developed to predict the outcome of MF, and therefore to identify patients who will benefit of an allogeneic HSCT. Patients with low risk MF are usually not selected for a transplant, whereas patients with intermediate or high risk MF are eligible. A separate issue, is how to predict the outcome of HSCT: we will outline a clinical molecular myelofibrosis transplant scoring system (MTSS), which predicts overall survival, ranging from 90% for low risk patients, to 20% for very high risk patients. We will also discuss transfusion burden and spleen size, as predictors of transplant outcome. The choice of a transplant platform including the conditioning regimen, the stem cell source and GvHD prophylaxis, are crucial for a successful program in MF, and will be outlined. Complications such as poor graft function, graft failure, GvHD and relapse of the disease, will also be reviewed. Finally we discuss monitoring the disease after HSCT with donor chimerism, driver mutations and hematologic data. We have made an effort to make this review as comprehensive and up to date as possible, and we hope it will provide some useful data for the clinicians.

Published
2022

177. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01

Author

Bonifazi, F., Pavoni, C., Peccatori, J., Giglio, F., Arpinati, M., Busca, A., Bernasconi, P., Grassi, A., Iori, A. P., Patriarca, F., Brunello, L., Di Grazia, C., Carella, A. M., Cilloni, D., Picardi, A., Proia, A., Santarone, S., Sorasio, R., Carluccio, P., Chiusolo, Patrizia, Cupri, A., Luppi, M., Nozzoli, C., Baronciani, D., Casini, M., Grillo, G., Musso, M., Onida, F., Palazzo, G., Parma, M., Tringali, S., Vacca, A., Vallisa, D., Sacchi, N., Oldani, E., Masciulli, A., Gheorghiu, A., Girmenia, C., Martino, M., Bruno, B., Rambaldi, A., Ciceri, F., Chiusolo P. (ORCID:0000-0002-1355-1587), Bonifazi, F., Pavoni, C., Peccatori, J., Giglio, F., Arpinati, M., Busca, A., Bernasconi, P., Grassi, A., Iori, A. P., Patriarca, F., Brunello, L., Di Grazia, C., Carella, A. M., Cilloni, D., Picardi, A., Proia, A., Santarone, S., Sorasio, R., Carluccio, P., Chiusolo, Patrizia, Cupri, A., Luppi, M., Nozzoli, C., Baronciani, D., Casini, M., Grillo, G., Musso, M., Onida, F., Palazzo, G., Parma, M., Tringali, S., Vacca, A., Vallisa, D., Sacchi, N., Oldani, E., Masciulli, A., Gheorghiu, A., Girmenia, C., Martino, M., Bruno, B., Rambaldi, A., Ciceri, F., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

The outcome of refractory/relapsed (R/R) acute leukemias is still dismal and their treatment represents an unmet clinical need. However, allogeneic transplantation (allo-HSCT) remains the only potentially curative approach in this setting. A prospective study (GANDALF-01, NCT01814488; EUDRACT:2012-004008-37) on transplantation with alternative donors had been run by GITMO using a homogeneous myeloablative conditioning regimen with busulfan, thiotepa and fludarabine while GVHD prophylaxis was stratified by donor type. The study enrolled 101 patients; 90 found an alternative donor and 87 ultimately underwent allo-HSCT. Two-year overall survival of the entire and of the transplant population (primary endpoint) were 19% and 22%, without significant differences according to disease, donor type and disease history (relapsed vs refractory patients). Two-year progression-free survival was 19% and 17% respectively. The cumulative incidences of relapse and non-relapse mortality were 49% and 33% at two years. Acute grade II-IV and chronic GVHD occurred in 23 and 10 patients. Dose intensification with a myeloablative two-alkylating regimen as sole strategy for transplanting R/R acute leukemia does seem neither to improve the outcome nor to control disease relapse. A pre-planned relapse prevention should be included in the transplant strategy in this patient population.

Published
2022

178. Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation

Author

Di Renzo, N., Musso, M., Scime, R., Cupri, A., Perrone, T., De Risi, C., Pastore, D., Guarini, A., Mengarelli, A., Benedetti, F., Mazza, P., Capria, S., Chiusolo, Patrizia, Cupelli, L., Federico, V., Bozzoli, V., Messa, A. R., Matera, R., Seripa, D., Codega, P., Bonizzoni, E., Specchia, G., Chiusolo P. (ORCID:0000-0002-1355-1587), Di Renzo, N., Musso, M., Scime, R., Cupri, A., Perrone, T., De Risi, C., Pastore, D., Guarini, A., Mengarelli, A., Benedetti, F., Mazza, P., Capria, S., Chiusolo, Patrizia, Cupelli, L., Federico, V., Bozzoli, V., Messa, A. R., Matera, R., Seripa, D., Codega, P., Bonizzoni, E., Specchia, G., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is particularly challenging for patients receiving highly emetogenic preparative regimens before autologous stem cell transplantation (ASCT) due to the daily and continuous emetogenic stimulus of the multiple day chemotherapy. While studies have shown effective prevention of CINV during the conditioning phase with NK1 receptor antagonist (NK1RA)-containing regimens, there have been no studies evaluating antiemetic use during chemomobilization prior to ASCT. Methods: This multicenter, open-label, phase IIa study evaluated the efficacy of every-other-day dosing of NEPA administered during chemomobilization in patients with relapsed-refractory aggressive non-Hodgkin’s lymphoma. Eighty-one patients participated. Results: Response rates were 77.8% for complete response (no emesis and no rescue use), 72.8% for complete control (complete response and no more than mild nausea), 86.4% for no emesis, and 82.7% for no rescue use during the overall phase (duration of chemomobilization through 48 h after). NEPA was well tolerated with no treatment-related adverse events reported. Conclusion: NEPA, administered with a simplified every-other-day schedule, show to be very effective in preventing CINV in patients at high risk of CINV undergoing to chemomobilization of hematopoietic stem cells prior to ASCT.

Published
2022

179. COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Author

Chiaretti, S., Bonifacio, M., Agrippino, R., Giglio, F., Annunziata, M., Curti, A., Del Principe, M. I., Salutari, P., Sciume, M., Delia, M., Armenio, M., Mancini, V., Mule, A., Grimaldi, F., Rege-Cambrin, G., Santoro, L., Lussana, F., Chiusolo, Patrizia, Pasciolla, C., Scattolin, A. M., Cerrano, M., Ciccone, M., Defina, M., Forghieri, F., Mazzone, C., Piccini, M., Ferrara, F., Pizzolo, G., Foa, R., Chiusolo P. (ORCID:0000-0002-1355-1587), Chiaretti, S., Bonifacio, M., Agrippino, R., Giglio, F., Annunziata, M., Curti, A., Del Principe, M. I., Salutari, P., Sciume, M., Delia, M., Armenio, M., Mancini, V., Mule, A., Grimaldi, F., Rege-Cambrin, G., Santoro, L., Lussana, F., Chiusolo, Patrizia, Pasciolla, C., Scattolin, A. M., Cerrano, M., Ciccone, M., Defina, M., Forghieri, F., Mazzone, C., Piccini, M., Ferrara, F., Pizzolo, G., Foa, R., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

N/A

Published
2022

180. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Author

Cerrano, M., Bonifacio, M., Olivi, M., Curti, A., Malagola, M., Dargenio, M., Scattolin, A. M., Papayannidis, C., Forghieri, F., Gurrieri, C., Tanasi, I., Zappasodi, P., Starza, R. L., Fracchiolla, N. S., Chiusolo, Patrizia, Giaccone, L., Del Principe, M. I., Giglio, F., Defina, M., Favre, C., Rizzari, C., Castella, B., Pizzolo, G., Ferrara, F., Chiaretti, S., Foa, R., Chiusolo P. (ORCID:0000-0002-1355-1587), Cerrano, M., Bonifacio, M., Olivi, M., Curti, A., Malagola, M., Dargenio, M., Scattolin, A. M., Papayannidis, C., Forghieri, F., Gurrieri, C., Tanasi, I., Zappasodi, P., Starza, R. L., Fracchiolla, N. S., Chiusolo, Patrizia, Giaccone, L., Del Principe, M. I., Giglio, F., Defina, M., Favre, C., Rizzari, C., Castella, B., Pizzolo, G., Ferrara, F., Chiaretti, S., Foa, R., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

n/a

Published
2022

181. GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms

Author

Malagola, M., Polverelli, N., Rubini, V., Martino, M., Patriarca, F., Bruno, B., Giaccone, L., Grillo, G., Bramanti, S., Bernasconi, P., De Gobbi, M., Natale, A., Terruzzi, E., Olivieri, A., Chiusolo, Patrizia, Carella, A. M., Casini, M., Nozzoli, C., Mazza, P., Bassi, S., Onida, F., Vacca, A., Falcioni, S., Luppi, M., Iori, A. P., Pavone, V., Skert, C., Carluccio, P., Borghero, C., Proia, A., Selleri, C., Sacchi, N., Mammoliti, S., Oldani, E., Ciceri, F., Russo, D., Bonifazi, F., Chiusolo P. (ORCID:0000-0002-1355-1587), Malagola, M., Polverelli, N., Rubini, V., Martino, M., Patriarca, F., Bruno, B., Giaccone, L., Grillo, G., Bramanti, S., Bernasconi, P., De Gobbi, M., Natale, A., Terruzzi, E., Olivieri, A., Chiusolo, Patrizia, Carella, A. M., Casini, M., Nozzoli, C., Mazza, P., Bassi, S., Onida, F., Vacca, A., Falcioni, S., Luppi, M., Iori, A. P., Pavone, V., Skert, C., Carluccio, P., Borghero, C., Proia, A., Selleri, C., Sacchi, N., Mammoliti, S., Oldani, E., Ciceri, F., Russo, D., Bonifazi, F., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

Today, allogeneic stem cell transplantation (allo-SCT) can be offered to patients up to age 70 to 72 years and represents one of the most effective curative treatments for many hematologic malignancies. The primary objective of the study was to collect data from the allo-SCTs performed in Italy between 2000 and 2017 in patients aged ≥60 years to evaluate the changes in safety and efficacy outcomes, as well as their distribution and characteristics over time. The Italian Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO) AlloEld study (ClinicalTrials.gov identifier NCT04469985) is a retrospective analysis of allo-SCTs performed at 30 Italian transplantation centers in older patients (age ≥60 years) between 2000 and 2017 (n = 1996). For the purpose of this analysis, patients were grouped into 3 time periods: time A, 2000 to 2005 (n = 256; 12%); time B, 2006 to 2011 (n = 584; 29%); and time C, 2012 to 2017 (n = 1156; 59%). After a median follow-up of 5.6 years, the 5-year nonrelapse mortality (NRM) remained stable (time A, 32.8%; time B, 36.2%; and time C, 35.0%; P = .5), overall survival improved (time A, 28.4%; time B, 31.8%; and time C, 37.3%; P = .012), and the cumulative incidence of relapse was reduced (time A, 45.3%; time B, 38.2%; time C, 30.0%; P < .0001). The 2-year incidence of extensive chronic graft-versus-host disease was reduced significantly (time A, 17.2%; time B, 15.8%; time C, 12.2%; P = .004). Considering times A and B together (2000 to 2011), the 2-year NRM was positively correlated with the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score; NRM was 25.2% in patients with an HCT-CI score of 0, 33.9% in those with a score of 1 or 2, and 36.1% in those with a score of 3 (P < .001). However, after 2012, the HCT-CI score was not significantly predictive of NRM. This study shows that the transplantation procedure in elderly patients became more effective over time. Relapse incidence remains t

Published
2022

182. Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation

Author

Delia, M., Carluccio, P., Gagliardi, V. P., Mestice, A., Chiusolo, Patrizia, Arpinati, M., Milone, G. A., Martino, M., Mazza, P., Ingrosso, C., Vacca, A., Saporiti, G., Zallio, F., Attolico, I., Pastore, D., Specchia, G., Albano, F., Musto, P., Chiusolo P. (ORCID:0000-0002-1355-1587), Delia, M., Carluccio, P., Gagliardi, V. P., Mestice, A., Chiusolo, Patrizia, Arpinati, M., Milone, G. A., Martino, M., Mazza, P., Ingrosso, C., Vacca, A., Saporiti, G., Zallio, F., Attolico, I., Pastore, D., Specchia, G., Albano, F., Musto, P., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

N/A

Published
2022

183. Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation

Author

Giammarco, S., Bellesi, Silvia, Metafuni, Elisabetta, Rossi, M., Minnella, Gessica, Bacigalupo, Andrea, Sica, S., Chiusolo, Patrizia, Bellesi S., Metafuni E., Minnella G., Bacigalupo A. (ORCID:0000-0002-9119-567X), Chiusolo P. (ORCID:0000-0002-1355-1587), Giammarco, S., Bellesi, Silvia, Metafuni, Elisabetta, Rossi, M., Minnella, Gessica, Bacigalupo, Andrea, Sica, S., Chiusolo, Patrizia, Bellesi S., Metafuni E., Minnella G., Bacigalupo A. (ORCID:0000-0002-9119-567X), and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

N/A

Published
2022

185. COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Author

Chiaretti, Sabina, primary, Bonifacio, Massimiliano, additional, Agrippino, Roberta, additional, Giglio, Fabio, additional, Annunziata, Mario, additional, Curti, Antonio, additional, Principe, Maria Ilaria Del, additional, Salutari, Prassede, additional, Sciumè, Mariarita, additional, Delia, Mario, additional, Armenio, Marco, additional, Mancini, Valentina, additional, Mulè, Antonino, additional, Grimaldi, Francesco, additional, Rege-Cambrin, Giovanna, additional, Santoro, Lidia, additional, Lussana, Federico, additional, Chiusolo, Patrizia, additional, Pasciolla, Crescenza, additional, Scattolin, Anna Maria, additional, Cerrano, Marco, additional, Ciccone, Maria, additional, Defina, Marzia, additional, Forghieri, Fabio, additional, Mazzone, Carla, additional, Piccini, Matteo, additional, Ferrara, Felicetto, additional, Pizzolo, Giovanni, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

186. Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation

Author

Delia, Mario, primary, Carluccio, Paola, additional, Gagliardi, Vito Pier, additional, Mestice, Anna, additional, Chiusolo, Patrizia, additional, Arpinati, Mario, additional, Milone, Giulio Antonio, additional, Martino, Massimo, additional, Mazza, Patrizio, additional, Ingrosso, Claudia, additional, Vacca, Adriana, additional, Saporiti, Giorgia, additional, Zallio, Francesco, additional, Attolico, Immacolata, additional, Pastore, Domenico, additional, Specchia, Giorgina, additional, Albano, Francesco, additional, and Musto, Pellegrino, additional

Published
2022
Full Text
View/download PDF

188. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus Acute Lymphoblastic Leukemia study

Author

Cerrano, Marco, Bonifacio, Massimiliano, Olivi, Matteo, Curti, Antonio, Malagola, Michele, Dargenio, Michelina, Scattolin, Anna Maria, Papayannidis, Cristina, Forghieri, Fabio, Gurrieri, Carmela, Tanasi, Ilaria, Zappasodi, Patrizia, La Starza, Roberta, Fracchiolla, Nicola Stefano, Chiusolo, Patrizia, Giaccone, Luisa, Del Principe, Maria Ilaria, Giglio, Fabio, Defina, Marzia, Favre, Claudio, Rizzari, Carmelo, Castella, Barbara, Pizzolo, Giovanni, Ferrara, Felicetto, Chiaretti, Sabina, and Foà, Robin

Subjects
Not available, Settore MED/15
Published
2022

190. BLINATUMOMAB AS A SUCCESSFUL AND SAFE THERAPY IN A DOWN SYNDROME PATIENT WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: CASE REPORTS AND LITERATURE. REVIEW

Author

SORA', Federica, primary, annunziata, mario, additional, laurenti, luca, additional, giammarco, sabrina, additional, chiusolo, patrizia, additional, innocenti, idanna, additional, autore, francesco, additional, metafuni, elisabetta, additional, galli, eugenio, additional, bacigalupo, andrea, additional, ferrara, felicetto, additional, and Sica, Simona, additional

Published
2022
Full Text
View/download PDF

192. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study

Author

Cerrano, Marco, primary, Bonifacio, Massimiliano, additional, Olivi, Matteo, additional, Curti, Antonio, additional, Malagola, Michele, additional, Dargenio, Michelina, additional, Scattolin, Anna Maria, additional, Papayannidis, Cristina, additional, Forghieri, Fabio, additional, Gurrieri, Carmela, additional, Tanasi, Ilaria, additional, Zappasodi, Patrizia, additional, La Starza, Roberta, additional, Fracchiolla, Nicola Stefano, additional, Chiusolo, Patrizia, additional, Giaccone, Luisa, additional, Del Principe, Maria Ilaria, additional, Giglio, Fabio, additional, Defina, Marzia, additional, Favre, Claudio, additional, Rizzari, Carmelo, additional, Castella, Barbara, additional, Pizzolo, Giovanni, additional, Ferrara, Felicetto, additional, Chiaretti, Sabina, additional, and Foà, Robin, additional

Published
2022
Full Text
View/download PDF

193. VEGF and IL-6 correlation in POEMS: a potential upcoming marker of active disease and early autologous BMT response.

Author

Laurenti, Luca, primary, Innocenti, Idanna, additional, Benintende, Giulia, additional, Tomasso, Annamaria, additional, Autore, Francesco, additional, Fresa, Alberto, additional, Vuono, Florenzia, additional, Baroni, Silvia, additional, Giannotta, Claudia, additional, Chiusolo, Patrizia, additional, Sorà, Federica, additional, and Sica, Simona, additional

Published
2022
Full Text
View/download PDF

194. Unrelated cord blood transplantation and post-transplant cyclophosphamide

Author

Bacigalupo, Andrea, Sica, Simona, Laurenti, Luca, Sora’, Federica, Giammarco, Sabrina, Metafuni, Elisabetta, Innocenti, Idanna, Autore, Francesco, Teofili, Luciana, Bianchi, Maria, Chiusolo, Patrizia, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Sica, Simona (ORCID:0000-0003-2426-3465), Laurenti, Luca (ORCID:0000-0002-8327-1396), Sora’, Federica (ORCID:0000-0002-9607-5298), Teofili, Luciana (ORCID:0000-0002-7214-1561), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Bacigalupo, Andrea, Sica, Simona, Laurenti, Luca, Sora’, Federica, Giammarco, Sabrina, Metafuni, Elisabetta, Innocenti, Idanna, Autore, Francesco, Teofili, Luciana, Bianchi, Maria, Chiusolo, Patrizia, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Sica, Simona (ORCID:0000-0003-2426-3465), Laurenti, Luca (ORCID:0000-0002-8327-1396), Sora’, Federica (ORCID:0000-0002-9607-5298), Teofili, Luciana (ORCID:0000-0002-7214-1561), and Chiusolo, Patrizia (ORCID:0000-0002-1355-1587)

Abstract

The number of unrelated cord blood transplants (UCBT) are declining in Europe, despite comparable outcome with grafts using unrelated donor peripheral bloodor bone marrow. The reasons for the decline may be due to the well-known slow engraftment and delayed immune reconstitution of UCBT, which may result in a significant risk of infections and non-relapse mortality (NRM).Neutrophil and platelet recovery can be shortened by direct intra-bone injection of CB cells, but immune recovery remains an issue, especially when anti-thymocyte globulin (ATG) is used in the conditioning regimen In the absence of ATG, grade III-IV acute graft versus host disease (GvHD) is reported to be 21%,6 and when ATG is added in the transplant platform, GvHD is reduced (15%), but immune reconstitution is delayed,leading to infectious complications, and late viral infections.4,7,8 The crucial role of ATG and the risk of over orunder exposure is further proven by the attempt to optimize ATG dose based on lymphocyte counts, rather thanpatient’s weight, and by carefully assessing the speed of CD4 recovery according to ATG dosing pre-transplant.An additional reason for the decline in numbers of UCBT is the competition of HLA haploidentical transplants(HAPLO), especially performed with post-transplant cyclophosphamide (PT-CY), as first described by the Baltimore group. We have been particularly impressedwith the speed of immune recovery of HAPLO transplants with PT-CY,13 with median CD4 counts on day +100 (190/µl) comparable to CD4 counts after HLA identical sibling grafts (229/µl), and significantly higher as compared to unrelated and cord blood grafts receiving ATG for GvHD prophylaxis.13 We therefore hypothesized that PT-CY would be an effective GvHD prophylaxis regimen for patients undergoing an UCBT and, by preventing GvHD in the absence of ATG, hematologic and immune recovery could be accelerated, as seen in the HAPLO setting. We are nowreporting a first case.

Published
2019

195. 'Secondary chronic myeloid leukemia': comparison between patients previously exposed or not to chemo- and/or radiotherapy

Author

Autore, Francesco, Sora', Federica, Chiusolo, Patrizia, Annunziata, Mario, Iurlo, Alessandra, Cattaneo, Daniele, Galimberti, Sara, Bajer, Jolanta Alina, Sica, Simona, Sorà, Federica (ORCID:0000-0002-9607-5298), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Sica, Simona (ORCID:0000-0003-2426-3465), Autore, Francesco, Sora', Federica, Chiusolo, Patrizia, Annunziata, Mario, Iurlo, Alessandra, Cattaneo, Daniele, Galimberti, Sara, Bajer, Jolanta Alina, Sica, Simona, Sorà, Federica (ORCID:0000-0002-9607-5298), Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

no abstract

Published
2019

196. Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid

Author

Autore, Francesco, Chiusolo, Patrizia, Sora', Federica, Giammarco, Sabrina, Laurenti, Luca, Innocenti, Idanna, Metafuni, Elisabetta, Piccirillo, Nicola, Pagano, Livio, Bacigalupo, Andrea, Leone, Giuseppe, Sica, Simona, Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Sorà, Federica (ORCID:0000-0002-9607-5298), Laurenti, Luca (ORCID:0000-0002-8327-1396), Piccirillo, Nicola (ORCID:0000-0002-1688-1987), Pagano, Livio (ORCID:0000-0001-8287-928X), Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Sica, Simona (ORCID:0000-0003-2426-3465), Autore, Francesco, Chiusolo, Patrizia, Sora', Federica, Giammarco, Sabrina, Laurenti, Luca, Innocenti, Idanna, Metafuni, Elisabetta, Piccirillo, Nicola, Pagano, Livio, Bacigalupo, Andrea, Leone, Giuseppe, Sica, Simona, Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Sorà, Federica (ORCID:0000-0002-9607-5298), Laurenti, Luca (ORCID:0000-0002-8327-1396), Piccirillo, Nicola (ORCID:0000-0002-1688-1987), Pagano, Livio (ORCID:0000-0001-8287-928X), Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

nd

Published
2019

197. Platelet-lysate-Expanded Mesenchymal Stromal Cells as a Salvage Therapy for Severe Resistant Graft-versus-Host Disease in a Pediatric Population

Author

Lucchini, Giovanna, Introna, Martino, Dander, Erica, Rovelli, Attilio, Balduzzi, Adriana, Bonanomi, Sonia, Salvadè, Agnese, Capelli, Chiara, Belotti, Daniela, Gaipa, Giuseppe, Perseghin, Paolo, Vinci, Paola, Lanino, Edoardo, Chiusolo, Patrizia, Orofino, Maria Grazia, Marktel, Sarah, Golay, Jose, Rambaldi, Alessandro, Biondi, Andrea, D'Amico, Giovanna, and Biagi, Ettore

Published
2010
Full Text
View/download PDF

200. Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors

Author

Corbingi, Andrea, primary, Metafuni, Elisabetta, additional, Di Salvatore, Mariantonietta, additional, Putzulu, Rossana, additional, Chiusolo, Patrizia, additional, Schinzari, Giovanni, additional, Massini, Giuseppina, additional, Rossi, Ernesto, additional, Zini, Gina, additional, Cassano, Alessandra, additional, Sica, Simona, additional, and Piccirillo, Nicola, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results